Trial Profile
Corrona Psoriasis (PSO) Registry
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Apremilast (Primary) ; Brodalumab (Primary) ; Ciclosporin (Primary) ; Etanercept (Primary) ; Guselkumab (Primary) ; Infliximab (Primary) ; Ixekizumab (Primary) ; Methotrexate (Primary) ; Risankizumab (Primary) ; Secukinumab (Primary) ; Ustekinumab (Primary)
- Indications Plaque psoriasis; Psoriasis; Psoriatic arthritis
- Focus Adverse reactions
- 31 Dec 2022 Results (n=113; CorEvitas Psoriasis Registry between 18 July 2017 and 10 March 2020) assessing the real-world effectiveness of guselkumab among patients living in the USA and Canada, published in the Dermatology and Therapy.
- 14 Nov 2022 Results assessing the real world effectiveness of apremilast by disease activity presented at the ACR Convergence 2022.
- 01 May 2022 Results reporting six month changes in disease status and patient-reported outcomes in patients with psoriasis initiating ixekizumab published in the Journal of Dermatological Treatment